Literature DB >> 21447316

The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice.

Lidice Bernardo1, Alequis Pavón, Lisset Hermida, Lázaro Gil, Iris Valdés, Sheila Cabezas, Ramón Linares, Mayling Alvarez, Ricardo Silva, Gerardo Guillén, Eszter Nagy, Petra Schlick, María G Guzmán.   

Abstract

Here we evaluated the suitability of the synthetic adjuvant IC31® to potentiate the protective capacity of PD5 protein (domain III of the envelope protein of dengue 2 virus fused to the carrier protein P64k). Unlike Alum, PD5 mixed with IC31® induced complete protection against virus challenge in mice and increased IFN-γ secretion after in vitro re-stimulation. The induced antibody response was highly specific to the homologous serotype and showed both IgG1 and IgG2a subtypes. IC31® is a promising adjuvant for PD5 recombinant protein based vaccination against dengue. Future work should address the suitability of PD5/IC31® formulations in non-human primate models.
Copyright © 2011. Published by Elsevier Ltd.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21447316     DOI： 10.1016/j.vaccine.2011.03.040

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  6 in total

1.  The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2.

Authors:  Lázaro Gil; Ernesto Marcos; Alienys Izquierdo; Laura Lazo; Iris Valdés; Peris Ambala; Lucy Ochola; Rikoi Hitler; Edith Suzarte; Mayling Álvarez; Prisilla Kimiti; James Ndung'u; Thomas Kariuki; María Guadalupe Guzmán; Gerardo Guillén; Lisset Hermida
Journal:  Immunol Cell Biol       Date:  2014-09-02       Impact factor: 5.126

2.  Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses.

Authors:  Chen-Yi Chiang; Ming-Hsi Huang; Chun-Hsiang Hsieh; Mei-Yu Chen; Hsueh-Hung Liu; Jy-Ping Tsai; Yi-Shiuan Li; Ching-Yun Chang; Shih-Jen Liu; Pele Chong; Chih-Hsiang Leng; Hsin-Wei Chen
Journal:  PLoS Negl Trop Dis       Date:  2012-05-15

3.  Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice.

Authors:  Chen-Yi Chiang; Chien-Hsiung Pan; Mei-Yu Chen; Chun-Hsiang Hsieh; Jy-Ping Tsai; Hsueh-Hung Liu; Shih-Jen Liu; Pele Chong; Chih-Hsiang Leng; Hsin-Wei Chen
Journal:  Sci Rep       Date:  2016-07-29       Impact factor: 4.379

4.  A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III.

Authors:  Dan Hu; Zhongyu Zhu; Shun Li; Yongqiang Deng; Yanling Wu; Nana Zhang; Vinita Puri; Chunyu Wang; Peng Zou; Cheng Lei; Xiaolong Tian; Yulu Wang; Qi Zhao; Wei Li; Ponraj Prabakaran; Yang Feng; Jane Cardosa; Chengfeng Qin; Xiaohui Zhou; Dimiter S Dimitrov; Tianlei Ying
Journal:  PLoS Pathog       Date:  2019-06-26       Impact factor: 6.823

5.  A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity.

Authors:  Laura Pattacini; Gregory J Mize; Jessica B Graham; Tayler R Fluharty; Tisha M Graham; Karen Lingnau; Benjamin Wizel; Beatriz Perdiguero; Mariano Esteban; Giuseppe Pantaleo; Mingchao Shen; Gregory A Spies; M Juliana McElrath; Jennifer M Lund
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

6.  Adjuvant-Mediated Epitope Specificity and Enhanced Neutralizing Activity of Antibodies Targeting Dengue Virus Envelope Protein.

Authors:  Denicar Lina Nascimento Fabris Maeda; Milene Tavares Batista; Lennon Ramos Pereira; Mariana de Jesus Cintra; Jaime Henrique Amorim; Camila Mathias-Santos; Sara Araújo Pereira; Silvia Beatriz Boscardin; Sandriana Dos Ramos Silva; Eliana L Faquim-Mauro; Vanessa Barbosa Silveira; Danielle Bruna Leal Oliveira; Stephen Albert Johnston; Luís Carlos de Souza Ferreira; Juliana Falcão Rodrigues
Journal:  Front Immunol       Date:  2017-09-25       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.